Conditions associated with increased sympathetic activity, such as resistant hypertension and heart failure, represent potential targets for carotid baroreceptor activation.

CVRx Inc. (Minneapolis, MN, USA) has developed a novel approach for implantable carotid baroreflex activation systems. The last generation device (Barostim neo) consists of an IPG and one carotid sinus electrode. The electrode is placed unilaterally, typically on the right carotid sinus via a small skin incision. The lead runs under the skin and is connected to the device under the skin near the collarbone. Meticulous implantation is crucial to avoid damage to baroreceptors and sinus nerves, and essential to achieve adequate blood pressure and heart rate responses to testing.

The clip above is showing two implantations.